TRCT
FBLG icon

Tower Research Capital (TRC)’s FibroBiologics FBLG Stock Holding History

Tower Research Capital (TRC)’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607 Sell
460
-445
-49% -$2.65K ﹤0.01% 4829
2025
Q4 		$4.07K Buy
905
+57
+7% +$402 ﹤0.01% 4264
2025
Q3 		$9.27K Buy
848
+87
+11% +$1.04K ﹤0.01% 4031
2025
Q2 		$9.47K Buy
761
+282
+59% +$5.09K ﹤0.01% 3990
2025
Q1 		$8.63K Buy
479
+248
+107% +$7.08K ﹤0.01% 3873
2024
Q4 		$9.25K Buy
231
+23
+11% +$1.23K ﹤0.01% 3920
2024
Q3 		$12.8K Buy
+208
New +$13.8K ﹤0.01% 3556

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM

Tower Research Capital (TRC)'s FBLG Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its FibroBiologics (FBLG) stake by 49% in Q1 2026, selling an estimated $2.65K and leaving 460 shares worth $607. The position accounts for ﹤0.01% of the portfolio, ranked #4829.

Tower Research Capital (TRC) first reported a position in FBLG in Q3 2024 and has held it in 7 quarters since. The position peaked at $12.8K in Q3 2024. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Tower Research Capital (TRC) held 460 shares of FibroBiologics worth $607 as of Q1 2026.
  • Tower Research Capital (TRC) sold 445 FibroBiologics shares in Q1 2026, an estimated $2.65K.
  • FibroBiologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4829 holding.
  • Tower Research Capital (TRC) first reported a position in FibroBiologics in Q3 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s FibroBiologics position peaked at $12.8K in Q3 2024.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.